Australia's Clarity Pharma jumps on deal with US co

Clarity Pharmaceuticals

11/11/2024 24:57

** Clarity Pharmaceuticals  CU6.AX  rises as much as 5.6% to
A$7.6, its highest since Oct. 9
    ** Co signs agreement with U.S.-based firm Nucleus
Radiopharma to produce their Cu-SAR-bisPSMA drug for the imaging
and treatment of prostate cancer
    ** Says agreement to expand production anticipating
recruitment demand for drug's phase II and phase III trials
    ** Stock posts largest intraday pct gain since Oct. 25
    ** YTD, CU6 has nearly tripled

 (Reporting by Nikita Maria Jino in Bengaluru)
 ((Nikita.Jino@thomsonreuters.com;))